BD to invest US$1.2B in pre-fillable syringe manufacturing capacity
Investment includes new manufacturing facility in Europe
FRANKLIN LAKES, N.J. — Becton, Dickinson and Company (BD), a global medical technology company, announced on Dec. 2 plans to invest approximately US$1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six global manufacturing locations and add a new manufacturing facility in Europe.
The new manufacturing facility in Europe is expected to be operational by the end of 2023. The investment will also fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network, all designed to maximize supply and reduce risks for pharmaceutical companies that rely on ready-to-fill syringes for their injectable drugs — including complex biologics, vaccines and small molecules.
“BD invented the ready-to-fill pre-fillable syringe technology, and today’s announcement demonstrates our continued commitment to better serve our customers,” said Eric Borin, worldwide president of BD Pharmaceutical Systems, in a prepared statement. “In addition, this investment positions BD to have the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines.”